Apostolos Pappas
Chief Scientific Officer Nogra Pharma
Seminars
Wednesday 4th November 2026
Phase III-Ready Topical PPARy Modulator for Moderateto- Severe Acne
2:00 pm
- Novel first-in-class topical PPARy modulator designed to target multiple acne pathways simultaneously, including inflammation, sebogenesis and keratinocyte dysfunction
- Phase IIb study in 450 patients demonstrated significant reductions in total lesion count and improved Investigator Global Assessment (IGA) success rates with a favourable safety and tolerability profile
- Phase III-ready programme with FDA and EMA-aligned development plans, positioning NAC-GED-0507 as a potential first new mechanistically differentiated topical acne therapy in decades
